New scan may spot hidden heart harm in childhood cancer survivors

NCT ID NCT01671696

Completed Knowledge-focused Sponsor: Connecticut Children's Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 80 childhood cancer survivors who had received high doses of anthracycline chemotherapy. Researchers used cardiac MRI and blood tests to find early signs of heart damage that standard tests might miss. The goal was to see if these advanced methods could detect hidden heart problems before symptoms appear, potentially allowing earlier treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better ways to detect heart damage early in childhood cancer survivors, potentially preventing heart failure.
What could go wrong: This is an observational study, not a treatment trial. The findings may not lead to new therapies, and the small size (80 participants) limits how widely results can be applied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder childhood malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASE

Contacts and locations

Locations

Connecticut Children's Medical Center

Hartford, Connecticut, 06106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.